Boehringer Ingelheim has raised hopes of a more patient-friendly option with the start of phase 2 testing of BI 1815368, ...

FDA approval was also granted in early 2025 to Susvimo (Roche) for the treatment of DME, which continuously delivers ranibizumab via the Port Delivery Platform, a refillable (every six months) eye ...

Roche has demonstrated the power of combining two of oncology’s hottest modalities—bispecifics and antibody-drug conjugates (ADCs)—in a Lunsumio-Polivy regimen in large B-cell lymphoma (LBCL ...

SNS Insider Reveals Sharp Growth in U.S. Retinal Biologics Market, Valued at USD 9.70 Billion in 2023 Capturing Over 43% Global Share Amid FDA Approvals, VEGF-A Dominance, and Accelerating R&D in ...

Roche has revealed good results from a phase 2 trial of its oral BTK drug fenebrutinib in relapsing multiple sclerosis as it waits for phase 3 data.

Roche presented results from the phase III SUNMO [NCT05171647] study showing Lunsumio (mosunetuzumab) administered subcutaneously in combination with Polivy (polatuzumab vedotin) demonstrated a ...

The latest international Roche Holding AG news and views from Reuters - one of the world's largest news agencies ...

Get Roche Holding AG (ROG.S) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments ...